SOLIGENIX, INC. Deferred Tax Assets, Goodwill and Intangible Assets
SOLIGENIX, INC. (SNGX) had Deferred Tax Assets, Goodwill and Intangible Assets of $1.40 million as of 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2025-03-21
- 2024-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $1.40M.
- 2023-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $1.41M.
- 2022-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $1.70M.
- 2021-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $1.95M.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets |
|---|---|
| 2024-12-31 | $1.40M 10-K · filed 2025-03-21 |
| 2023-12-31 | $1.41M 10-K · filed 2025-03-21 |
| 2022-12-31 | $1.70M 10-K · filed 2024-03-15 |
| 2021-12-31 | $1.95M 10-K · filed 2023-03-31 |
| 2020-12-31 | $817.00K 10-K · filed 2022-03-29 |
| 2019-12-31 | $1.05M 10-K · filed 2021-03-30 |
| 2018-12-31 | $1.16M 10-K · filed 2020-03-30 |
| 2017-12-31 | $1.29M 10-K · filed 2019-03-26 |
| 2016-12-31 | $1.92M 10-K · filed 2018-03-15 |
| 2015-12-31 | $2.09M 10-K · filed 2017-03-27 |
| 2014-12-31 | $2.14M 10-K · filed 2016-03-24 |
| 2013-12-31 | $127.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |